Clinical Effect of Addition of Beraprost Sodium to Pioglitazone Treatment on the Blood Glucose Levels in Patients with Type 2 Diabetes Mellitus

Abstract

In recent years, the number of patients with type 2 diabetes mellitus caused by insulin resistance has continued to increase in Japan. Insulin resistance is considered to be closely related to the risk of cardiovascular diseases and atherosclerotic diseases, represented by arteriosclerosis obliterans (ASO). Therefore, improvement of insulin resistance is one of the important strategies in the treatment of type 2 diabetes mellitus. At present, α-glucosidase inhibitors, incretin-related drugs, and thiazolidinediones are among the most important oral hypoglycemic drugs used to improve insulin resistance. In this study, the effect of beraprost sodium, a prostaglandin I2 derivative, in the treatment of type 2 diabetes mellitus was investigated. In type 2 diabetic patients with ASO who were under treatment with pioglitazone, additional treatment with beraprost sodium exerted a significant synergistic effect in reducing the serum HbA1c levels as compared to treatment with pioglitazone alone. This result indicates that concomitant administration of pioglitazone and beraprost sodium may be useful in the treatment of diabetes ­mellitus.

Key words

beraprost sodium - pioglitazone - HbA1c - type 2 diabetes

• References

• 1 Rajwani A, Cubbon RM, Wheatcroft SB. Cell-specific insulin resistance: implications for atherosclerosis. Diabetes Metab Res Rev 2012; 28: 627-634
• 2 Sato N, Kaneko M, Tamura M et al. The prostacyclin analog beraprost sodium ameliorates characteristics of metabolic syndrome in obese Zucker (fatty) rats. Diabetes 2010; 59: 1092-1100
• 3 Inoue E, Ichiki T, Takeda K et al. Beraprost sodium, a stable prostacyclin analogue, improves insulin resistance in high-fat diet-induced obese mice. J Endocrinol 2012; 213: 285-291
• 4 Fujiwara K, Nagasaka A, Nagata M et al. A stable prostacyclin analogue reduces high serum TNF-α levels in diabetic patients. Exp Clin Endocrinol Diabetes 2004; 112: 390-394
• 5 Kubota T, Kubota N, Kumagai H et al. Impaired insulin signaling in endothelial cells reduces insulin-induced glucose uptake by skeletal muscle. Cell Metab 2011; 13: 294-307
• 6 Hernanz R, Martín Á, Péres-Girón JV et al. Pioglitazone treatment increases COX-2-derived prostacyclin production and reduces oxidative stress in hypertensive rats: role in vascular function. Br J Pharmacol 2012; 166: 1303-1319
• 7 Majima T, Komatsu Y, Doi K et al. Safety and efficacy of low-dose pioglitazone (7.5 mg/day) vs. standard-dose pioglitazone (15 mg/day) in Japanese women with type 2 diabetes mellitus. Endocr J 2006; 53: 325-330
• 8 Aso Y, Hara K, Ozeki N et al. Low-dose pioglitazone increases serum high molecular weight adiponectin and improves glycemic control in Japanese patients with poorly controlled type 2 diabetes. Diabetes Res Clin Pract 2009; 85: 147-152
• 9 Chatzipanteli K, Rudolph S, Axelrod L. Coordinate control of lipolysis by prostaglandin E2 and prostacyclin in rat adipose tissue. Diabetes 1992; 41: 927-935